Perampanel Dosing and Management for Focal-Onset Seizures
Start perampanel at 2 mg once daily at bedtime and titrate by 2 mg increments at weekly intervals to a maintenance dose of 8-12 mg daily, with mandatory close monitoring for serious psychiatric and behavioral reactions including aggression, hostility, and homicidal ideation. 1
Starting Dose
- Standard initiation: 2 mg once daily at bedtime for adults and pediatric patients ≥4 years old 1
- With enzyme-inducing AEDs (phenytoin, carbamazepine, oxcarbazepine): Start at 4 mg once daily at bedtime due to reduced perampanel plasma levels 1
Titration Schedule
The FDA-approved titration is weekly 2 mg increments, though real-world evidence suggests slower titration may improve tolerability 1. A Canadian study demonstrated that titrating by 2 mg every 4 weeks (rather than weekly) achieved a 78.4% retention rate at 6 months with 36% seizure freedom, suggesting slower titration is better tolerated in clinical practice 2. The FDA label notes that slower titration was better tolerated across all antiepileptic drugs studied 3.
Practical titration approach:
- Increase by 2 mg increments
- Standard patients: weekly intervals minimum
- Consider 2-4 week intervals for better tolerability, particularly in patients with psychiatric history 2, 4
- Patients with hepatic impairment: increase every 2 weeks minimum 1
Maintenance Dosing
Target maintenance dose: 8-12 mg once daily 1
- Some patients respond to 4 mg daily 1
- 12 mg daily provides greater seizure reduction than 8 mg but with substantially increased adverse reactions 1
- Recommended maintenance range: 8-12 mg daily balancing efficacy and tolerability 1
Special populations:
- Mild hepatic impairment: Maximum 6 mg daily
- Moderate hepatic impairment: Maximum 4 mg daily
- Severe hepatic impairment: Not recommended 1
Critical Monitoring Requirements
Psychiatric and Behavioral Monitoring (BLACK BOX WARNING)
This is the most important safety concern with perampanel. Serious or life-threatening psychiatric reactions have occurred in patients with AND without prior psychiatric history 1.
Monitor closely for:
- Aggression, hostility, irritability, anger
- Homicidal ideation and threats
- Changes in mood, behavior, or personality atypical for the patient
- Monitoring intensity: Particularly during titration and at higher doses 1
Management of psychiatric symptoms:
- Reduce dose if symptoms occur
- Discontinue immediately if symptoms are severe or worsening 1
- Advise patients and caregivers to contact healthcare provider immediately if these reactions occur 1
Common Adverse Events to Monitor
The most frequently reported adverse events across clinical trials and real-world studies include 5, 4, 6:
- Dizziness/vertigo (21.8-50% of patients)
- Somnolence (up to 36.4%)
- Fatigue (up to 13.6%)
- Ataxia
- Headache
- Gait disturbance
- Weight gain (only non-neurological adverse effect consistently reported) 5
Real-world discontinuation rates due to adverse events range from 13.7-31.8% 4, 7, 6.
Drug Interactions Requiring Dose Adjustment
CYP3A4 enzyme inducers significantly reduce perampanel levels 1:
- Start at 4 mg daily (instead of 2 mg)
- Titrate by 2 mg increments weekly
- Maximum studied dose: 12 mg daily
- When inducers are added or withdrawn, closely monitor and adjust perampanel dose accordingly 1
Common enzyme-inducing AEDs: phenytoin, carbamazepine, oxcarbazepine 1
Efficacy Expectations
Based on real-world and clinical trial data:
- 50% responder rates: 52-82% depending on seizure type 2, 7
- Seizure freedom rates: 25-67.4% at 6-12 months 2, 7, 8
- Retention rates: 54.5-77.7% at 12 months 2, 4, 8
- Median seizure frequency reduction: 55.4% at 6 months in real-world Italian study 6
Patients with shorter epilepsy duration respond better (median 3 years duration showed superior response, p=0.032) 9.
Common Pitfalls to Avoid
- Titrating too rapidly: Weekly increases are the minimum interval, but 2-4 week intervals improve tolerability 2
- Inadequate psychiatric monitoring: Behavioral changes can occur without prior psychiatric history 1
- Missing drug interactions: Failing to start at 4 mg when enzyme-inducing AEDs are co-administered 1
- Ignoring hepatic impairment: Requires dose caps and slower titration 1
- Pushing to 12 mg without careful evaluation: Higher doses increase adverse events substantially 1